Advertisement
GKOS vs ISRG
Which Stock Would AI Choose? Glaukos Corporation (GKOS) vs. Intuitive Surgical (ISRG) Stock Comparison
Key Takeaways
- GKOS (Glaukos Corporation) has delivered sharply positive relative performance in recent quarters, while ISRG (Intuitive Surgical) has lagged the broader market in 2026 despite steady double-digit revenue growth.
- Glaukos is a high-growth, still-unprofitable ophthalmology innovator, whereas Intuitive Surgical is a profitable, cash-generative market leader in robotic-assisted surgery.
- Both stocks offer recurring-revenue characteristics, but Intuitive Surgical derives roughly 85% of sales from instruments, accessories, and services, creating a more mature, defensible model.
- Sentiment diverged recently: Glaukos pulled back from highs on insider selling and reimbursement headlines, while Intuitive Surgical rebounded into its next earnings report.
- Risk profiles differ materially — Glaukos carries execution and reimbursement risk, while Intuitive Surgical faces rising competition and a premium valuation.
Introduction
Investors evaluating medical technology often weigh high-growth, early-stage innovators against established, profitable franchises. Glaukos Corporation and Intuitive Surgical represent opposite ends of that spectrum, even though both operate within the broader medical-device and healthcare technology space. This stock comparison is relevant for growth-oriented traders seeking momentum and catalysts, as well as long-term investors weighing stability, cash flow, and market positioning. By examining recent performance, business models, and sentiment shifts, readers can better assess how these two names fit differing risk tolerances and time horizons in the current market environment.
GKOS Overview and Recent Performance
GKOS (Glaukos Corporation) develops pharmaceutical and medical-technology therapies for glaucoma, corneal disorders, and retinal diseases. Its flagship iDose TR implant has driven rapid adoption in interventional glaucoma treatment, while the recently launched Epioxa corneal cross-linking therapy has opened a new growth market in keratoconus, a progressive corneal condition. The company is also advancing an expanding pipeline across multiple ophthalmic therapeutic platforms.
Recent market activity has been strong but volatile. In its most recent quarterly report, Glaukos posted record net sales of approximately $185.6 million, up about 50% year over year, and raised its full-year revenue guidance to a range of $680–700 million. The stock has gained sharply over the past year, significantly outperforming the S&P 500, though recent weeks brought a pullback as insider selling overshadowed otherwise positive Phase 3 and Phase 4 clinical data. Glaukos remains unprofitable on a GAAP (generally accepted accounting principles) basis but carries no debt and is narrowing its losses as margins expand.
ISRG Overview and Recent Performance
ISRG (Intuitive Surgical) is the global leader in robotic-assisted surgery, known primarily for its da Vinci surgical systems and the Ion endoluminal lung-biopsy platform. The company's model is anchored by a large installed base of systems that generate high-margin recurring revenue from instruments, accessories, and service contracts.
Fundamentally, Intuitive Surgical continues to grow. Its most recent quarter showed revenue of about $2.89 billion, up 19% year over year, with worldwide procedure growth near 16% and adjusted earnings per share (EPS) rising roughly 28%. Despite this, the stock has declined roughly 25–29% year to date after peaking above $600 in January, as investors weighed moderating procedure growth, competition in China, the FDA (U.S. Food and Drug Administration) clearance of rival systems such as Johnson & Johnson's OTTAVA, and the impact of GLP-1 weight-loss drugs on bariatric procedures. Recent weeks, however, brought a rebound as sentiment improved ahead of its next earnings release.
Trending AI Robots
Tickeron's Trending AI Robots page curates a select group of algorithmic trading bots from a broader universe of hundreds of AI-powered systems that trade thousands of different tickers. Each bot follows its own trading style, strategy, timeframe, performance record, and set of tickers, so only those judged most suitable for current market conditions earn a place in this featured section. The page highlights measurable statistics — such as trade counts, win rates, and historical performance ranges — to help users evaluate how different strategies are positioned. Because market conditions shift continuously, browsing the Trending AI Robots page offers a useful way to see which automated approaches are currently in favor before conducting your own analysis.
Head-to-Head Comparison
These two companies occupy different corners of the healthcare technology market. Glaukos competes in interventional ophthalmology, where growth is driven by surgeon adoption, reimbursement expansion, and product launches such as iDose TR and Epioxa. Its addressable market is expanding rapidly, but its financial profile remains unprofitable, making it more sensitive to execution and payer decisions. Intuitive Surgical, by contrast, competes in robotic-assisted surgery, where its moat rests on a large installed base, decades of clinical data, and high-margin recurring revenue. Its growth is steadier but increasingly contested by Medtronic, Stryker, and Johnson & Johnson.
Recent momentum also diverged. Glaukos outperformed the market dramatically over the past year before consolidating in recent weeks, while Intuitive Surgical underperformed in 2026 before a recent rebound. On valuation, Intuitive Surgical trades at a premium forward price-to-earnings (P/E) multiple relative to mature device peers, while Glaukos is valued on revenue growth and pipeline optionality rather than earnings. Risk factors differ accordingly: Glaukos faces clinical, reimbursement, and path-to-profitability risk, whereas Intuitive Surgical faces competitive encroachment and the challenge of justifying a premium valuation if procedure growth decelerates further.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor GKOS for trend consistency and near-term momentum, given its sustained relative outperformance, record revenue growth, and active pipeline catalysts. However, that momentum carries elevated volatility and unprofitability risk. Intuitive Surgical presents stronger fundamentals, cash flow, and market leadership, but its downtrend and valuation compression suggest less favorable near-term positioning. In probabilistic terms, the AI framework would lean toward Glaukos on trend and catalyst metrics while acknowledging that Intuitive Surgical offers greater stability for longer-horizon, risk-averse investors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GKOS is a StrongBuy and ISRG is a Hold.
GKOS's RSI Oscillator ascends from oversold territory
The RSI Oscillator for GKOS moved out of oversold territory on September 28, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 19 similar instances when the indicator left oversold territory. In 17 of the 19 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on GKOS as a result. In 76 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for GKOS just turned positive on October 02, 2026. Looking at past instances where GKOS's MACD turned positive, the stock continued to rise in 51 of 59 cases over the following month. The odds of a continued upward trend are 86%.
GKOS moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where GKOS advanced for three days, in 248 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 10-day moving average for GKOS crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GKOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
GKOS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GKOS entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 33 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. GKOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.284) is normal, around the industry mean (2.923). P/E Ratio (-54.083) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (12.570) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (15.456) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ISRG in -1.73% downward trend, sliding for three consecutive days on October 14, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ISRG declined for three days, in 162 of 264 cases, the price declined further within the following month. The odds of a continued downward trend are 61%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ISRG moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 11 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 30%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
ISRG broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ISRG as a result. In 51 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The 10-day moving average for ISRG crossed bullishly above the 50-day moving average on September 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 5 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 45%.
Following a +2.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where ISRG advanced for three days, in 210 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 183 of 264 cases where ISRG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. ISRG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 80 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ISRG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.325) is normal, around the industry mean (4.952). P/E Ratio (48.430) is within average values for comparable stocks, (36.644). Projected Growth (PEG Ratio) (1.931) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).
GKOS | ISRG | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 87 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 91 Overvalued | 81 Overvalued | |
PROFIT vs RISK RATING 1..100 | 33 | 80 | |
SMR RATING 1..100 | 96 | 51 | |
PRICE GROWTH RATING 1..100 | 36 | 42 | |
P/E GROWTH RATING 1..100 | 54 | 71 | |
SEASONALITY SCORE 1..100 | 50 | 49 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ISRG's Valuation (81) in the Medical Specialties industry is in the same range as GKOS (91). This means that ISRG’s stock grew similarly to GKOS’s over the last 12 months.
GKOS's Profit vs Risk Rating (33) in the Medical Specialties industry is somewhat better than the same rating for ISRG (80). This means that GKOS’s stock grew somewhat faster than ISRG’s over the last 12 months.
ISRG's SMR Rating (51) in the Medical Specialties industry is somewhat better than the same rating for GKOS (96). This means that ISRG’s stock grew somewhat faster than GKOS’s over the last 12 months.
GKOS's Price Growth Rating (36) in the Medical Specialties industry is in the same range as ISRG (42). This means that GKOS’s stock grew similarly to ISRG’s over the last 12 months.
GKOS's P/E Growth Rating (54) in the Medical Specialties industry is in the same range as ISRG (71). This means that GKOS’s stock grew similarly to ISRG’s over the last 12 months.
| GKOS | ISRG | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 30% |
| Stochastic ODDS (%) | 2 days ago 70% | 2 days ago 61% |
| Momentum ODDS (%) | 2 days ago 83% | 2 days ago 65% |
| MACD ODDS (%) | 2 days ago 86% | N/A |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 64% |
| TrendMonth ODDS (%) | 2 days ago 78% | 2 days ago 66% |
| Advances ODDS (%) | 2 days ago 78% | 3 days ago 66% |
| Declines ODDS (%) | 7 days ago 67% | 9 days ago 61% |
| BollingerBands ODDS (%) | 2 days ago 67% | 2 days ago 43% |
| Aroon ODDS (%) | 2 days ago 66% | 2 days ago 69% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GKOS’s FA Score shows that 1 FA rating(s) are green while ISRG’s FA Score has 0 green FA rating(s).
- GKOS’s FA Score: 1 green, 4 red.
- ISRG’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GKOS’s TA Score shows that 5 TA indicator(s) are bullish while ISRG’s TA Score has 4 bullish TA indicator(s).
- GKOS’s TA Score: 5 bullish, 5 bearish.
- ISRG’s TA Score: 4 bullish, 4 bearish.
Price Growth
GKOS (@Medical/Nursing Services) experienced а +5.34% price change this week, while ISRG (@Pharmaceuticals: Other) price change was +1.88% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.63%. For the same industry, the average monthly price growth was -3.82%, and the average quarterly price growth was +8.73%.
Reported Earning Dates
GKOS is expected to report earnings on Oct 28, 2026.
ISRG is expected to report earnings on Jan 26, 2027.
Industries' Descriptions
@Medical/Nursing Services (-1.62% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+0.63% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
ISRG and
Correlation & Price change
A.I.dvisor indicates that over the last year, ISRG has been closely correlated with BSX. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if ISRG jumps, then BSX could also see price increases.
| Ticker / NAME | Correlation To ISRG | 1D Price Change % | ||
|---|---|---|---|---|
| ISRG | 100% | -2.26% | ||
| BSX - ISRG | 73% Closely correlated | -2.35% | ||
| SYK - ISRG | 64% Loosely correlated | -2.23% | ||
| NTRA - ISRG | 54% Loosely correlated | +1.84% | ||
| GKOS - ISRG | 51% Loosely correlated | +1.97% | ||
| PODD - ISRG | 49% Loosely correlated | -0.52% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EGGQ | 47.50 | 1.43 | +3.10% |
| NestYield Visionary ETF (EGGQ) | |||
| CRF | 5.96 | 0.09 | +1.53% |
| Cornerstone Total Return Fund | |||
| TSEP | 26.00 | 0.13 | +0.51% |
| FT Vest Emerging Market Buffer ETF - September (TSEP) | |||
| VIG | 243.66 | 0.59 | +0.24% |
| Vanguard Dividend Appreciation ETF (VIG) | |||
| SCMC | 24.42 | N/A | N/A |
| Sterling Capital Multi-Strategy Income ETF (SCMC) | |||